Understanding payer perceptions of health inequalities in health technology assessment and reimbursement decision-making
Disparities in health outcomes and access to health care among different population groups are becoming increasingly important to be considered in health technology assessment (HTA) and reimbursement decision-making. To ensure that health inequalities are appropriately and systematically considered by all stakeholders, there is a need for a clear framework, better methods to measure inequality, and a shared understanding of how these factors should be considered alongside clinical outcomes.
In the ISPOR 2024 session titled, “Payer Perceptions of Health Inequalities in Reimbursement Decision Making: Implications for the Pharmaceutical Industry,” Kuldeep Singh and Tijana Ignjatovic of Genesis Research Group delved into this complex landscape. They shared results from a qualitative payer survey on perceptions of health equity and its role in decision-making, providing valuable insights into current stakeholder views on this critical issue.
Health inequity in HTA and reimbursement decision-making: current perspectives
Kuldeep Singh set the scene by referencing the WHO and NICE definitions of health inequity, highlighting a shared description of the term as, “an unjust, avoidable, and systematic difference in health outcomes and access to health resources among different population groups.” Looking at the available literature, Singh revealed that while some HTA agencies consider health equity in their decision-making, published frameworks are sparse. Notably, agencies like NICE and ICER have guidelines, but others, like HAS in France, do not. Even with existing frameworks, health inequalities are not consistently incorporated into HTA decisions. Various methods, including distributional cost-effectiveness analysis and multiple criteria decision analysis, can address health equity, but these approaches are still in their early stages and have their own complexities. Therefore, it is crucial to monitor how HTA methods and requirements will evolve.
To explore this further, Kuldeep Singh introduced Tijana Ignjatovic to share results from a survey conducted by Genesis Research Group on stakeholder views of health inequalities and their impact on the pharmaceutical industry.
Click the button below to continue reading our deep dive into the survey results.
READ RESULTS OF THE PAYER SURVEY HERE
If you would like to find out more about RPR and the accelerated stakeholder insights provided by Genesis Research Group, visit their website or contact [email protected].
About the speakers
Tijana Ignjatovic, Executive Director, Genesis Research Group, UK
Tijana Ignjatovic is an Executive Director within the Access and Pricing Team and has over 15-years of consultancy experience in market access. In her time both in analysis and consultancy roles, Tijana has worked on multiple research methodologies and applied this experience, along with her market access knowledge, to lead and deliver numerous payer research projects in a broad range of therapeutic areas, including oncology, cardiovascular, infectious diseases, neurology, rheumatology, and many others. With a keen eye for detail, Tijana leverages her deep understanding of the industry and market access to quickly visualize and make connections on complex projects and provide strategic input to optimize clients’ market access strategy and value messaging across different payer requirements.
Kuldeep Singh, Executive Vice President, Genesis Research Group, UK
Dr Kuldeep Singh is a physician and healthcare expert with 20+ years of industry experience. He specializes in HTA, market access, HEOR, RWE, and pricing for pharmaceuticals and vaccines. He held senior positions at Novartis and WHO, and has executed diverse projects in market access, pricing, health economics, and HTA for companies across Europe and USA. He has an MPH from University College London/Humboldt-Universität zu Berlin/Karolinska Institutet, and an MBA from London Business School.
Sponsorship for this Deep Dive was provided by Genesis Research Group